Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition.
about
CAR models: next-generation CAR modifications for enhanced T-cell functionDifferent Subsets of T Cells, Memory, Effector Functions, and CAR-T ImmunotherapyChimeric Antigen Receptors Modified T-Cells for Cancer TherapyMesothelin-Targeted CARs: Driving T Cells to Solid TumorsSmart CARs engineered for cancer immunotherapyA Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors.Chimeric Antigen Receptor T-Cells: New Approaches to Improve Their Efficacy and Reduce ToxicityAdvances in umbilical cord blood cell therapy: the present and the future.Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells.Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.Therapeutic T cell engineering.Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T.Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.
P2860
Q26745600-8439CBF2-78C3-4251-B9DC-64BCE50CDB1CQ26752955-311E9DB4-D689-4FEF-B7BF-D74C6ABE0770Q26773309-7BAC55C1-E489-4EA2-8068-385785A5C187Q26778759-76A3C852-D7F6-415B-9E10-C1C5C2CCBF73Q28087236-F8C70122-7B4A-442A-91B5-D49DD9FC519CQ36709308-8835B269-FF11-4428-9FAD-C13BA85923F4Q38640367-117BC1AC-B843-463A-B5C4-7FED1CC91D80Q38734758-4C9C01BB-7368-455C-B1AC-2FCD7CAF2033Q38787449-A729AAD5-FC73-4CF2-9893-2A0AAC19A257Q39189908-FBCD1419-1DDE-4D26-B087-D2DBE3E87614Q40199809-4F222449-A5A4-417E-97A6-C8E4E09527A6Q40965523-CD501DB9-E805-49BE-B343-101D4A2928DAQ47193084-3D5F45F0-467E-48C3-960E-A3B59FB01A17Q48525241-2FAD2BF8-3AD5-4861-AE85-B921878A3C32Q49280922-2BAF4DC9-3EC3-415C-AC71-D9B86F26C4E9
P2860
Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Tumor-Targeted Human T Cells E ...... Circumvent CTLA-4 Inhibition.
@ast
Tumor-Targeted Human T Cells E ...... Circumvent CTLA-4 Inhibition.
@en
type
label
Tumor-Targeted Human T Cells E ...... Circumvent CTLA-4 Inhibition.
@ast
Tumor-Targeted Human T Cells E ...... Circumvent CTLA-4 Inhibition.
@en
prefLabel
Tumor-Targeted Human T Cells E ...... Circumvent CTLA-4 Inhibition.
@ast
Tumor-Targeted Human T Cells E ...... Circumvent CTLA-4 Inhibition.
@en
P2093
P2860
P1433
P1476
Tumor-Targeted Human T Cells E ...... Circumvent CTLA-4 Inhibition.
@en
P2093
Gertrude Gunset
Jason Plotkin
Jon Arnason
Maud Condomines
Michel Sadelain
Reuben Benjamin
P2860
P304
P356
10.1371/JOURNAL.PONE.0130518
P407
P577
2015-06-25T00:00:00Z